A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5

University of Oxford

Status and phase: Completed; Phase 1

Conditions: Plasmodium Falciparum; Malaria

Treatments: Biological: ChAd63 RH5 full dose; Biological: ChAd63 RH5 low dose; Biological: MVA RH5 full dose; Biological: MVA RH5 low dose

Study type: Interventional

Funder types: Other

Identifiers

NCT02181088

2013-005458-31 (EudraCT Number)

VAC057

Details and patient eligibility

About

The purpose of this study is to assess two new malaria vaccines, ChAd63 RH5 and MVA RH5, at different doses and alone or in combination. The study will enable us to assess the safety of the vaccines and the extent of the immune response in healthy volunteers. We will do this by giving volunteers one or two vaccinations, doing blood tests and collecting information about any symptoms that occur after vaccination. This is the first trial to use these vaccines in humans.

Enrollment: 26 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults aged 18 to 50 years
• Able and willing (in the Investigator's opinion) to comply with all study requirements
• Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
• For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of screening and vaccination
• Agreement to refrain from blood donation during the course of the study
• Provide written informed consent

Exclusion criteria

• Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
• Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data.
• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
• Any confirmed or suspected immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products.
• Any history of anaphylaxis in reaction to vaccination
• Pregnancy, lactation or willingness/intention to become pregnant during the study
• History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
• History of serious psychiatric condition
• Any other serious chronic illness requiring hospital specialist supervision
• Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
• Suspected or known injecting drug abuse in the 5 years preceding enrolment
• Seropositive for hepatitis B surface antigen (HBsAg)
• Seropositive for hepatitis C virus (antibodies to HCV)
• History of clinical malaria (any species)
• Travel to a malaria endemic region during the study period or within the previous six months
• Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
• Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
• Inability of the study team to contact the volunteer's general practitioner (GP) to confirm medical history and safety to participate

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

26 participants in 4 patient groups

Group 1 (ChAd63 RH5 low dose)

Experimental group

Description:

1 dose of ChAd63 RH5 5 x 10\^9 vp intramuscularly

Treatment:

Biological: ChAd63 RH5 low dose

Group 2A (ChAd63 RH5 full dose)

Experimental group

Description:

1 dose of ChAd63 RH5 at 5 x 10\^10 vp intramuscularly

Treatment:

Biological: ChAd63 RH5 full dose

Group 2B (ChAd63 RH5 full dose and MVA RH5 low dose)

Experimental group

Description:

1 dose of ChAd63 RH5 at 5 x 10\^10 vp intramuscularly and 1 dose MVA RH5 at 1 x 10\^8 pfu 8 weeks later intramuscularly

Treatment:

Biological: MVA RH5 low dose

Biological: ChAd63 RH5 full dose

Group 2C (ChAd63 RH5 full dose and MVA RH5 full dose)

Experimental group

Description:

1 dose of ChAd63 RH5 at 5 x 10\^10 vp intramuscularly and 1 dose MVA RH5 at 2 x 10\^8 pfu 8 weeks later intramuscularly

Treatment:

Biological: MVA RH5 full dose

Biological: ChAd63 RH5 full dose